COMP <GO>
JANX vs LTGO // EV/EBITDA & P/E VALUATION
Janux Therapeutics Inc. (NASDAQ) VS. Latigo Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: JANX 2
— LTGO 0
■ METRIC PARITY
LAST: $17.83 (-1.22%) • MKT CAP: $1.09B
valuation
—
LAST: $15.54 (-1.83%) • MKT CAP: $1.03B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JANX VS. LTGO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JANX | LTGO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.80% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.64% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 38.0 | +13.92 | JANX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.09B | $1.03B | $59.8M | JANX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JANX REV | LTGO REV | JANX GROSS % | LTGO GROSS % | JANX FCF | LTGO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$83.3M | — |
| FY 2024 | $0 | — | — | — | -$44.2M | — |
| FY 2023 | $0 | — | — | — | -$50.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JANX // BETA —
LTGO // BETA —